Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Chemotherapy is the primary established systemic treatment for patients with triple-negative
breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of …

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct
morphological features and clinical behaviors. Although morphology is often associated with …

Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in
breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …

Breast cancer is a heterogeneous disease, comprising multiple entities associated with
distinctive histological and biological features, clinical presentations and behaviours and …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …

Estrogen receptor (ER) expression and proliferative activity are established prognostic
factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene …

Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Introduction Breast cancer is a heterogeneous group of tumors, and can be subdivided on
the basis of histopathological features, genetic alterations and gene-expression profiles …